Updated Jul 16, 2026
Kim Helen Susan is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market purchases: $15.03M.
Helen Susan Kim is identified as an insider of Aktis Oncology, Inc. (ticker AKTS) in the SEC filing with CIK 0001422772 dated 2026-01-12. The filing indicates zero purchases and zero sales and does not disclose her specific role within Aktis Oncology. Aktis Oncology is a clinical-stage radiopharmaceutical company focused on targeted alpha therapies for solid tumors.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-01-12 | AKTS | Aktis Oncology, Inc. | P — Open-market purchase | 22.5K | $18.00 | $406K |
| 2026-01-12 | AKTS | Aktis Oncology, Inc. | J — Other acquisition / disposition | 134.8K | — | |
| 2026-01-12 | AKTS | Aktis Oncology, Inc. | P — Open-market purchase | 812.5K | $18.00 | $14.62M |
| 2026-01-12 | AKTS | Aktis Oncology, Inc. | J — Other acquisition / disposition | 4.86M | — |
Helen Susan Kim is identified as an insider of Aktis Oncology, Inc. (ticker AKTS) in the SEC filing with CIK 0001422772 dated 2026-01-12. The filing indicates zero purchases and zero sales and does not disclose her specific role within Aktis Oncology. Aktis Oncology is a clinical-stage radiopharmaceutical company focused on targeted alpha therapies for solid tumors.…
Recorded transactions: 2 open-market purchases ($15.03M) and 0 open-market sales () across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Kim Helen Susan profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.